World Health Organization. Programmatic update: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. (http://www.who.int/hiv/PMTCT_update.pdf). Accessed 13 May 2016.
Townsend, CL, et al.
Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011. AIDS
2014; 28: 1049–1057.
Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. (http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf). Accessed 28 March 2016.
Watts, DH, et al.
Complications according to mode of delivery among human immunodeficiency virus-infected women with CD4 lymphocyte counts of < or = 500/microL. American Journal of Obstetrics & Gynecology
2000; 183: 100–107.
Bulterys, M, et al.
Sexual behavior and injection drug use during pregnancy and vertical transmission of HIV-1. Journal of Acquired Immune Deficiency Syndromes
1997; 15: 76–82.
European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS
2001; 15: 761–770.
Vayssière, C, et al.
Fetal growth restriction and intra-uterine growth restriction: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians. European Journal of Obstetrics & Gynecology and Reproductive Biology
2015; 193: 10–18.
Unterscheider, J, et al.
Optimizing the definition of intrauterine growth restriction: the multicenter prospective PORTO Study. American Journal of Obstetrics and Gynecology
2013; 208: 290. e1–6.
Bruzzone, B, et al.
Impact of extensive HIV-1 variability on molecular diagnosis in the Congo basin. Journal of Clinical Virology
2010; 47: 372–375.
Agresti, A. An Introduction to Categorical Data Analysis, 2nd edn.
Hoboken: John Wiley & Sons, 2007, pp. 357.
Fay, MP, Proschan, MA. Wilcoxon-Mann-Whitney or t-test? On assumptions for hypothesis tests and multiple interpretations of decision rules. Statistics Surveys
2010; 4: 1–39.
Peters, L, Klein, MB. Epidemiology of hepatitis C virus in HIV-infected patients. Current Opinion in HIV and AIDS
2015; 10: 297–302.
Townsend, CL, et al.
Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS
2008; 22: 973–981.
Liuzzi, G, et al.
Pregnancy outcomes in HIV-infected women of advanced maternal age. HIV Clinical Trials
2013; 14: 110–119.
Aebi-Popp, K, et al.
Missed opportunities among HIV-positive women to control viral replication during pregnancy and to have a vaginal delivery. Journal of Acquired Immune Deficiency Syndromes
2013; 64: 58–65.
Huntington, SE, et al.
Predictors of pregnancy and changes in pregnancy incidence among HIV positive women accessing HIV clinical care at 13 large UK clinics. AIDS
2013; 27: 95–103.
Aebi-Popp, K, et al.
National Guidelines for the prevention of mother-to-child transmission of HIV across Europe - how do countries differ?
European Journal of Public Health
2013; 23: 1053–1058.
Kind, C, et al.
Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. Swiss Neonatal HIV Study Group. AIDS
1998; 12: 205–210.
The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1—a meta-analysis of 15 prospective cohort studies. New England Journal of Medicine
1999; 340: 977–987.
Duong, T, et al.
Vertical transmission rates for HIV in the British Isles: estimates based on surveillance data. British Medical Journal
1999; 319: 1227–1229.
European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clinical Infectious Diseases
2005; 40: 458–465.
Connor, EM, et al.
Reduction of maternal–infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. New England Journal of Medicine
1994; 331: 1173–1180.
Lorenzi, P, et al.
Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS
1998; 12: F241–F247.
Townsend, CL, et al.
Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS
2007; 21: 1019–1026.
Cotter, AM, et al.
Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth?
The Journal of Infectious Diseases
2006; 193: 1195–1201.
Kourtis, AP, et al.
Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS
2007; 21: 607–615.
Fowler, MG, et al.
Benefits and risks of antiretroviral therapy for perinatal HIV prevention. New England Journal Medicine
2016; 375: 1726–1737.
European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. Journal of Acquired Immune Deficiency Syndromes
2003; 32: 380–387.
Hoffman, MC, et al.
Pregnancy at or beyond age 40 years is associated with an increased risk of fetal death and other adverse outcomes. American Journal of Obstetrics & Gynecology
2007; 196: e11–13.
Tuomala, RE, et al.
Antiretroviral therapy during pregnancy and the risk of an adverse outcome. New England Journal of Medicine
2002; 346: 1863–1870.
Pritham, UA, Troese, M, Stetson, A. Methadone and buprenorphine treatment during pregnancy. What are the effects?
Nursing for Women's Health
2007; 11: 558–567.
Mozurkewich, EL, Rayburn, WF. Buprenorphine and methadone for opioid addiction during pregnancy. Obstetrics and Gynecology Clinics of North America
2014; 41: 241–253.
Kakko, J, Heilig, M, Sarman, I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug and Alcohol Dependence
2008; 96: 69–78.
Brogly, SB, et al.
Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. American Journal of Epidemiology
2014; 180: 673–686.